Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Bruce Cree
Photo of Bruce Cree
Bruce Cree

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with relapsing Multiple Sclerosis (RMS).

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Keywords

Multiple Sclerosis (MS) Relapsing multiple sclerosis Multiple Sclerosis Sclerosis elezanumab Elezanumab Dose 1 Elezanumab Dose 2

Eligibility

You can join if…

Open to people ages 18-65

  • Subject has diagnosis of relapsing remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24 months
  • Subject has cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with multiple sclerosis (MS)
  • Subject has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test

You CAN'T join if...

  • Subjects must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening

Locations

  • UCSF School of Medicine - Neurology /ID# 204251
    San Francisco California 94143-0003 United States
  • Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249
    Berkeley California 94705-2017 United States

Lead Scientist at UCSF

  • Bruce Cree
    Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis in the Department of Neurology at the University of California San Francisco. Dr. Cree completed his MD and PhD in Biochemistry at UCSF. His neurology residency training was at Columbia University.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03737851
Phase
Phase 2
Study Type
Interventional
Last Updated